

**Childhood Vaccine Availability Table**  
**-- Effective December 2017 --**

**Eligibility Categories:**

- **All Children:** Vaccine provided by MDPH for identified cohorts, regardless of insurance status through 18 years of age.
- **Vaccines for Children (VFC) Program Only:** Vaccine provided by MDPH for identified cohorts through 18 years of age who are: 1) uninsured; 2) enrolled in MassHealth/Medicaid; 3) American Indian or Alaska Native; or 4) underinsured (insurance does not cover the vaccine) and seen at a federally qualified community health center. Children enrolled in the Children’s Medical Security Plan (CMSP) and sCHIP are also covered using state funds.

(Please note vaccines available only for VFC eligible groups appear shaded.)

Vaccine	Eligibility	DPH-Supplied Vaccine Available For:
<b>DT</b>	All	<ul style="list-style-type: none"> <li>• Children aged 2 months – 6 years for whom pertussis vaccine is contraindicated</li> </ul>
<b>DTaP</b>	All	<ul style="list-style-type: none"> <li>• All children aged 2 months – 6 years</li> </ul>
<b>DTaP-Hep B-IPV</b> (Pediarix <sup>®</sup> )	All	<ul style="list-style-type: none"> <li>• All children aged 2 months – 6 years for the first 3 doses of DTaP and IPV and any dose of Hep B at 2, 4 and 6 months</li> <li>• Not approved for dose 4 or 5 of the DTaP series <u>or</u> dose 4 of the IPV series</li> </ul>
<b>DTaP-IPV-Hib</b> (Pentacel <sup>®</sup> )	All	<ul style="list-style-type: none"> <li>• All children aged 2 months – 4 years for the first 4 doses of DTaP, IPV and Hib at 2, 4, 6 and 15 – 18 months</li> </ul>
<b>DTaP-IPV</b> (Kinrix <sup>®</sup> /Quadracel <sup>®</sup> )	All	<ul style="list-style-type: none"> <li>• All children aged 4 – 6 years for routine immunization for the 5<sup>th</sup> dose of the DTaP series and 4<sup>th</sup> dose of the IPV series</li> <li>• Not approved for the first 3 doses of DTaP and IPV <u>or</u> dose 4 of the DTaP series</li> </ul>
<b>Hep A</b>	All	<ul style="list-style-type: none"> <li>• Routine vaccination of the 1<sup>st</sup> and 2<sup>nd</sup> dose for children aged 12 – 23 months</li> <li>• Catch-up vaccination of children aged 2 – 18 years</li> </ul>
<b>Hep B</b>	All	<ul style="list-style-type: none"> <li>• All children through 18 years of age</li> </ul>
<b>Hib</b>	All	<ul style="list-style-type: none"> <li>• All children aged 2 – 59 months</li> <li>• Children aged &gt; 5 years in an ACIP-recommended high risk group*</li> </ul>
<b>HPV</b>	All	<ul style="list-style-type: none"> <li>• All children 9 – 18 years of age</li> </ul> <p>Note: routinely recommended at 7<sup>th</sup> grade entry, 11 – 12 years of age</p>
<b>Influenza</b>	All	<ul style="list-style-type: none"> <li>• All children aged 6 months – 18 years</li> </ul>
<b>MCV4-ACWY</b> (Meningococcal Conjugate) (MDPH does not provide meningococcal polysaccharide vaccine)	All	<ul style="list-style-type: none"> <li>• All adolescents 11 – 18 years of age</li> </ul> <p>Note: first dose routinely recommended at 7<sup>th</sup> grade entry, 11 – 12 years of age, and second dose at 16 – 18 years of age</p> <ul style="list-style-type: none"> <li>• ACIP-recommended high risk* children 2 months – 18 years, all doses, including boosters. Schedule depends on age and formulation. Note: Menveo approved beginning at 2 months and Menactra at 9 months.</li> </ul>

Vaccine	Eligibility	DPH Supplied Vaccine Available For:
<b>MenB</b>	All	<ul style="list-style-type: none"> <li>ACIP-recommend high risk* children 10 – 18 years of age</li> </ul>
	VFC Only	<ul style="list-style-type: none"> <li>May be considered for adolescents 16 – 18 years of age to provide short term protection against most strains of serogroup B meningococcal disease (permissive recommendation).</li> </ul>
<b>MMR</b>	All	<ul style="list-style-type: none"> <li>All children aged 12 months – 18 years</li> </ul>
<b>MMRV</b>	All	<ul style="list-style-type: none"> <li>All children aged 12 months – 12 years who require both MMR and varicella vaccines</li> </ul> <p><u>Note:</u> ACIP recommends the 1st dose in the series for children 12 – 47 months be given as separate injections of MMR and varicella vaccines and generally recommends MMRV for the 2<sup>nd</sup> dose in the series or for the 1<sup>st</sup> dose for those <math>\geq</math> 48 months. See <a href="#">ACIP</a> statement for full guidance.</p>
<b>PCV13</b> (Pneumococcal Conjugate)	All	<ul style="list-style-type: none"> <li>All children aged 2 – 59 months</li> <li>High risk* children through age 71 months</li> <li>Subset of highest risk children aged 6 – 18 years</li> </ul>
<b>PPSV23</b> (Pneumococcal Polysaccharide)	All	<ul style="list-style-type: none"> <li>Children aged 2 – 18 years who are in an ACIP-recommended high risk group*</li> </ul>
<b>Polio</b>	All	<ul style="list-style-type: none"> <li>All children aged 2 months – 18 years</li> </ul>
<b>Rotavirus</b>	All	<ul style="list-style-type: none"> <li>All infants aged 6 weeks – 8 months 0 days</li> </ul>
<b>Td</b>	All	<ul style="list-style-type: none"> <li>All children aged 7 – 18 years</li> </ul>
<b>Tdap</b>	All	<ul style="list-style-type: none"> <li>All children aged 7 – 18 years</li> </ul> <p>Note: routinely recommended at 7<sup>th</sup> grade entry, 11 – 12 years of age</p>
<b>Varicella</b>	All	<ul style="list-style-type: none"> <li>All children aged 12 months – 18 years</li> </ul>

\*High risk children as defined by the ACIP, including those exposed in an outbreak setting who are not fully vaccinated. For ACIP recommendations, see the Recommended Childhood Immunization Schedule

<https://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html>

For the complete ACIP recommendations, see <http://www.cdc.gov/vaccines/acip/index.html>.